Jacobio Pharmaceuticals Group Co., Ltd. (stock code 01167, JACOBIO-B) disclosed a minor reduction in its share capital following an on-market buy-back executed on 1 June 2026.

• Transaction details – Shares repurchased: 110,400 ordinary shares – Price range: HKD 4.50-4.54 per share – Volume-weighted average price: HKD 4.52 per share – Aggregate consideration: HKD 0.50 million

• Capital structure impact – Issued shares (excluding treasury) fell to 783.95 million from 784.06 million, a 0.014 % contraction. – Treasury-share balance rose to 7.80 million. – Total issued shares (including treasury) remained unchanged at 791.76 million.

• Repurchase mandate utilisation – The buy-back was conducted under the mandate approved on 10 June 2025, which permits up to 78.87 million shares to be repurchased. – Cumulative repurchases under this mandate now total 4.78 million shares, representing 0.61 % of the company’s issued share count at the mandate date.

• Post-repurchase restrictions In line with Hong Kong Listing Rules, Jacobio Pharmaceuticals is subject to a moratorium on issuing new shares or disposing of treasury shares until 1 July 2026.

Director Xiaojie Wang confirmed that the repurchase complied with all relevant Main Board requirements and that no material changes have been made to the company’s previously filed explanatory statement.